Table 2.
Compounds inducing pyroptosis signal pathways in related cancers.
| Classification | Compounds | Cancer types | Mechanisms of Pyroptosis Induction |
References |
|---|---|---|---|---|
| Chemotherapy drugs | Doxorubicin, Actinomycin-D, Bleomycin, Topotecan | Lung cancer | Caspase3/GSDME | [30] |
| Doxorubicin | Melanoma | eEF-2K/caspase3/ GSDME | [76] | |
| Lobaplatin | Colon cancer | ROS/JNK/caspase3 /GSDME |
[22] | |
| Cisplatin, Paclitaxel | Lung cancer | Caspase3/GSDME | [21] | |
| Cisplatin+PLK1 inhibitor | ESCC | Bax/caspase3/GSDME | [77] | |
| Cisplatin + Decitabine | Colon cancer and Breast carcinoma |
Caspase3/GSDME | [78] | |
| Reagents | L61H10 | Lung cancer | NF-κB/caspase3/GSDME | [79] |
| Metformin | ESCC | miR-497/PELP1/caspase1 /GSDMD |
[80] | |
| As2O3-NPs | HCC | Caspase3/GSDME | [81] | |
| Natural products | Galangin | Glioblastoma | LC3B/caspase3/GSDME | [55] |
| Anthocyanin | OSCC | NLRP3/caspase1/GSDMD | [82] | |
| Dioscin | Osteosarcoma | Caspase3/GSDME | [83] | |
| Berberine | HCC | Caspase1 | [84] | |
| Huaier | NSCLC | NLRP3/caspase1 | [85] |
ESCC: esophageal squamous cell carcinoma. OSCC: oral squamous cell carcinoma. HCC: hepatocellular carcinoma. NSCLC: non-small cell lung cancer. GSDME: gasderminE. EGFR: epidermal growth factor receptor. ROS: reactive oxygen species. JNK: c-jun n-terminal kinase.Bax: BCL-2 associated X. PELP1: Proline-, glutamic acid- and leucine-rich protein-1.